Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy by Hughes, Richard A.C. et al.
Cochrane Database of Systematic Reviews
Corticosteroids for chronic inflammatory demyelinating
polyradiculoneuropathy (Review)
Hughes RAC, Mehndiratta MM, Rajabally YA
Hughes RAC, Mehndiratta MM, Rajabally YA.
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD002062.
DOI: 10.1002/14651858.CD002062.pub4.
www.cochranelibrary.com
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
13ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
17DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Corticosteroids versus control, Outcome 1 Improvement in impairment after 12 weeks
excluding those who did not complete the study. . . . . . . . . . . . . . . . . . . . . . . 30
Analysis 1.2. Comparison 1 Corticosteroids versus control, Outcome 2 Improvement in impairment after 12 weeks
including those who did not complete the study. . . . . . . . . . . . . . . . . . . . . . . 30
Analysis 1.3. Comparison 1 Corticosteroids versus control, Outcome 3 Number of patients improved after 12 weeks
excluding those who did not complete the study. . . . . . . . . . . . . . . . . . . . . . . 31
Analysis 1.4. Comparison 1 Corticosteroids versus control, Outcome 4 Number of patients who showed improvement after
12 weeks including those who did not complete the study. . . . . . . . . . . . . . . . . . . 31
Analysis 2.1. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 1 Remission at 12 months. . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Analysis 2.2. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 2 ≥ 1 point improvement on INCAT disability score at 12 months. . . . . . . . . . . . 32
Analysis 2.3. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 3 Change in MRC sum score at endpoint. . . . . . . . . . . . . . . . . . . . . 33
Analysis 2.4. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 4 Change in grip strength at endpoint. . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 2.5. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 5 Sleeplessness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 2.6. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 6 Cushingoid facies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Analysis 2.7. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 7 Weight gain 1 - 3 kg. . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 2.8. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone,
Outcome 8 Weight gain > 3 kg. . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
37APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
41INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iCorticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Corticosteroids for chronic inflammatory demyelinating
polyradiculoneuropathy
Richard AC Hughes1, Man Mohan Mehndiratta2 , Yusuf A Rajabally3
1MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK. 2Department of Neu-
rology, Janakpuri Superspecialty Hospital, New Delhi, India. 3Aston Brain Centre, Aston University, Birmingham, UK
Contact address: Richard AC Hughes, MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery,
PO Box 114, Queen Square, London, WC1N 3BG, UK. rhughes11@btinternet.com, richard.hughes@ucl.ac.uk.
Editorial group: Cochrane Neuromuscular Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 11, 2017.
Citation: Hughes RAC, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneu-
ropathy. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD002062. DOI: 10.1002/14651858.CD002062.pub4.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing and remitting paralysing illness,
probably due to an autoimmune response, which should benefit from corticosteroid treatment. Non-randomised studies suggest that
corticosteroids are beneficial. Two commonly used corticosteroids are prednisone and prednisolone. Both are usually given as oral tablets.
Prednisone is converted into prednisolone in the liver so that the effect of the two drugs is usually the same. Another corticosteroid,
dexamethasone, is more potent and is used in smaller doses. The review was first published in 2001 and last updated in 2015; we
undertook this update to identify any new evidence.
Objectives
To assess the effects of corticosteroid treatment for CIDP compared to placebo or no treatment, and to compare the effects of different
corticosteroid regimens.
Search methods
On 8 November 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials,
MEDLINE, and Embase for randomised trials of corticosteroids for CIDP. We searched clinical trials registries for ongoing trials.
Selection criteria
We included randomised controlled trials (RCTs) or quasi-RCTs of treatment with any corticosteroid or adrenocorticotrophic hormone
for CIDP, diagnosed by an internationally accepted definition.
Data collection and analysis
Two authors extracted data from included studies and assessed the risk of bias independently. The intended primary outcome was
change in disability, with change in impairment after 12 weeks and side effects as secondary outcomes. We assessed strength of evidence
using the GRADE approach.
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Main results
One non-blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome
for this systematic review. The trial had a high risk of bias. Neuropathy Impairment Scale scores after 12 weeks improved in 12 of
19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for
improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low-quality evidence). The trial did not report side effects in detail,
but one prednisone-treated participant died.
A double-blind RCT comparing daily standard-dose oral prednisolone with monthly high-dose oral dexamethasone in 40 participants
reported none of the prespecified outcomes for this review. The trial had a low risk of bias, but the quality of evidence was limited as
it came from a single small study. There was little or no difference in number of participants who achieved remission (RR 1.11; 95%
CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate-quality evidence), or change in disability or impairment after one
year (low-quality evidence). Change of grip strength or Medical Research Council (MRC) scores demonstrated little or no difference
between groups (moderate-quality to low-quality evidence). Eight of 16 people in the prednisolone group and seven of 24 people in
the dexamethasone group deteriorated. Side effects were similar with each regimen, except that sleeplessness was less common with
monthly dexamethasone (low-quality evidence) as was moon facies (moon-shaped appearance of the face) (moderate-quality evidence).
Experience from large non-randomised studies suggests that corticosteroids are beneficial, but long-term use causes serious side effects.
Authors’ conclusions
We are very uncertain about the effects of oral prednisone compared with no treatment, because the quality of evidence from the only
RCT that exists is very low. Nevertheless, corticosteroids are commonly used in practice, supported by very low-quality evidence from
observational studies. We also know from observational studies that corticosteroids carry the long-term risk of serious side effects. The
efficacy of high-dose monthly oral dexamethasone is probably little different from that of daily standard-dose oral prednisolone. Most
side effects occurred with similar frequencies in both groups, but with high-dose monthly oral dexamethasone moon facies is probably
less common and sleeplessness may be less common than with oral prednisolone. We need further research to identify factors that
predict response.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Review question
We reviewed the evidence about the benefits and harms of using corticosteroids for the treatment of chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP).
Background
CIDP is an uncommon paralysing disease that occurs when nerves outside the brain and spinal cord become inflamed. It produces
slowly evolving weakness and numbness of the limbs. Some people have recurrent periods of worsening followed by improvement or
remission. We wanted to discover the answers to two questions: firstly, whether use of corticosteroids is helpful; and secondly, whether
one type of corticosteroid treatment is better than another. This is an update of a review first published in 2001 and last updated in
2014.
Study characteristics
We found one randomised controlled trial (RCT) addressing each question. We did not find any new trials for this update.
A 1982 US study compared daily prednisone tablets for 12 weeks with no treatment. Thirty-five people took part. Fourteen participants
received prednisone (10 male and four female, with a median age of 46.5 years) and 14 did not receive prednisone (nine male and five
female, with a median age of 50 years). Those taking part and the trialists were aware of which treatment the participants received (i.e.
they were not ’blinded’), which carries a risk of bias.
The second study compared two six-month corticosteroid treatment regimens: daily standard-dose prednisolone tablets, and high-dose
dexamethasone tablets for four days each month. Multiple European centres did the trial, which reported its findings in 2010. Forty-
one people took part but one person withdrew after one day because they did not want to continue and the diagnosis was wrong. Of
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those who continued, 24 (18 men and six women, average age 59.9 years) received monthly dexamethasone and 16 (10 men and six
women, average age 60.8 years) received daily prednisolone.
There was no commercial support for either study. Funding for both came from an academic centre or charitable funds.
Key results
Neither included study reported our preferred primary outcome, which was a disability score.
After 12 weeks, in the trial of prednisone compared to no treatment, 12 of 19 participants on prednisone improved compared with
five of 16 participants not on prednisone, based on measurement of disease severity by neurologists. Thus, improvement was about
twice as common with prednisone. The small numbers in the trial and its limitations meant that even with this difference we are very
uncertain about the size of any effect of prednisone. The trial authors did not report side effects in detail, but one person who received
prednisone died. Corticosteroids are commonly used for CIDP in practice, based on favourable reports from non-randomised studies.
Corticosteroids are well known to cause side effects, especially when people take large doses for a long time.
In the RCT comparing two corticosteroid regimens, 10 of 24 people on monthly dexamethasone and six of 16 people on daily
prednisolone were well and off treatment after a year, which indicates effects that are probably similar. Changes in grip strength and
scores of muscle strength were also probably similar between the treatment groups. Monthly dexamethasone and daily prednisolone
had similar side effects to one another, except that with high-dose monthly dexamethasone, sleeplessness may be less common and a
moon-shaped facial appearance is probably less common.
Quality of the evidence
The benefit and harm from prednisone in CIDP is uncertain. The quality of evidence is very low because only one small randomised
trial with a high risk of bias is available.
Monthly dexamethasone and daily prednisolone may be of similar benefit in CIDP, but monthly dexamethasone may have fewer side
effects.
Date
The evidence is up to date to 8 November 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prednisone for chronic inflammatory demyelinating polyradiculoneuropathy
Patient or population: people with chronic inf lammatory demyelinat ing polyradiculoneuropathy
Settings: hospital specialist neurological outpat ient department
Intervention: prednisone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk or value Corresponding risk or
value
Control (no treatment) Prednisone
Change in disability af-
ter one year
- - - - - Not measured
Change in impairment
after 12 weeks (exclud-
ing those who did not
complete the study)
NIS score (range 0 to
280)
The mean improvement
in impairment af ter 12
weeks, excluding those
who did not complete
the study in the control
group was
3.5 points
The mean improvement
in impairment af ter 12
weeks, excluding those
who did not complete
the study in the pred-
nisone group was
17.14 points higher
(4.39 lower to 38.67
higher)
- 28
(1 RCT)
⊕©©©
Very low1,2
Not stat ist ically signif i-
cant
Change in impairment
after 12 weeks (includ-
ing those who did not
complete the study)
NIS (range 0 to 280)
The mean improvement
in impairment af ter 12
weeks, including those
who did not complete
the study in the control
group was
- 2.4 points (i.e. 2.4
points worse)
The mean improvement
in impairment af ter 12
weeks, including those
who did not complete
the study in the pred-
nisone group was
11.6 points higher
(9.39 lower to 32.58
higher)
- 35
(1 RCT)
⊕©©©
Very low1
Not stat ist ically signif i-
cant
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Number of partici-
pants improved after
12 weeks (excluding
those who did not com-
plete the study)
NIS score (range 0 to
280)
357 per 1000 857 per 1000
(411 to 1000)
RR 2.40
(CI 1.15 to 5)
28
(1 RCT)
⊕©©©
Very low1,2
Stat ist ically signif icant
more improvement, but
at high risk of bias
Number of partici-
pants improved after
12 weeks (including
those who did not com-
plete the study)
NIS (range 0 to 280)
312 per 1000 631 per 1000
(281 to 1000)
RR 2.02
(CI 0.9 to 4.52)
35
(1 RCT)
⊕©©©
Very low1,2
Not stat ist ically signif i-
cant
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NIS: Neuropathy Impairment Scale; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1We downgraded the quality of evidence three t imes: twice for very serious study lim itat ions and once for imprecision. The
trial was not blinded and randomisat ion was not concealed. The 95% CI were wide.
2Seven part icipants were excluded, giving high risk of bias in favour of prednisone.
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B A C K G R O U N D
Description of the condition
Chronic inflammatory demyelinating polyradiculoneuropathy
(CIDP) is characterised by chronic progressive or relapsing weak-
ness and numbness, especially of the limbs. It affects motor and
sensory nerve fibres, but may present with predominantly mo-
tor or sensory symptoms. The cerebrospinal fluid (CSF) protein
concentration is usually increased. The aetiology of CIDP is pre-
sumed to be autoimmune (Hughes 2006; Mathey 2015; Vallat
2010). Biopsy and autopsy studies of active lesions in the periph-
eral nerves and spinal roots show oedema, lymphocytic infiltra-
tion, and macrophage-associated segmental demyelination.
The disease is uncommon. It affects males and females of all ages
but is more common in the elderly. Estimates of prevalence range
from 2 to 9 per 100,000. Prevalences of 2.84 per 100,000 in
England (Mahdi-Rogers 2014) and 3.58 per 100,000 in North
Italy are typical (Chiò 2007). In the English study, 32% of people
with CIDP required aid to walk on the prevalence date.
Early, large case series described the clinical picture, but did not
precisely define the disease (Barohn 1989; Dyck 1975; McCombe
1987; Prineas 1976). Research criteria for the diagnosis were pro-
posed by the Ad Hoc Subcommittee of the American Academy
of Neurology Acquired Immunodeficiency Disease (AIDS) Task
Force (AAN 1991). These required fulfilment of clinical and elec-
trophysiological criteria for a diagnosis of “probable” CIDP, and
fulfilment of pathological criteria for a diagnosis of “definite”
CIDP inwhich the progressive phase lastedmore than eight weeks.
These criteria have been extensively debated. More liberal criteria
have beenwidely adopted, including in this review (Van denBergh
2010).
In this reviewwe relied on the authors’ diagnosis of CIDPprovided
that it fulfilled the spirit of the definition of “probable” CIDP pro-
posed by the AdHoc Subcommittee (AAN 1991). Apart from the
neurophysiological evidence of multifocal demyelination, there
are no reliable diagnostic tests for CIDP, and the diagnosis is,
in part, one of exclusion. Differential diagnoses include heredi-
tary, metabolic, vasculitic, amyloid, paraneoplastic, and parapro-
teinaemic neuropathies. There is a debate about whether some
cases of neuropathy associated with diabetes mellitus, systemic
lupus erythematosus, and monoclonal gammopathy are due to
CIDP. Because of the uncertainty, we planned to exclude such
cases from this review. We also excluded multifocal motor neu-
ropathy with conduction block, which is generally recognised to
be a separate entity and does not respond to corticosteroids (Van
Schaik 2010).
Description of the intervention
Treatments for CIDP are aimed at suppressing an abnormal au-
toimmune response. Corticosteroids are potent immunosuppres-
sants. Two commonly used corticosteroids are prednisone and
prednisolone. Both are usually given as oral tablets. Prednisone is
converted into prednisolone in the liver so that the effect of the
two drugs is usually the same. Another corticosteroid, called dex-
amethasone, is more potent and is used in smaller doses.
Austin 1958 reported dramatic improvement with corticosteroids
and relapse following withdrawal, even when the withdrawal
was done under blind conditions. From then onwards, corti-
costeroids were extensively used for CIDP, although only one
randomised trial comparing corticosteroids with controls was
ever done (Dyck 1982). Subsequently, large retrospective studies
on CIDP reported significant improvement after corticosteroids
(Barohn 1989; Cocito 2010; Kuwabara 2006; McCombe 1987).
The usual regimen has been long-term oral prednisone or pred-
nisolone, with the dose titrated according to the individual’s re-
sponse. Alternative regimens of pulsed high-dose intravenous or
oral corticosteroids have been tried, and pulsed high-dose oral
dexamethasone has been compared with standard-dose oral pred-
nisolone in the PREDICT 2010 trial.
Although corticosteroids were the first treatment to be used in
CIDP, plasma exchange and intravenous immunoglobulin (IVIg)
have since been used in randomised controlled trials (RCTs) and
shown inCochrane reviews to be efficacious short-term treatments
(Eftimov 2013; Mehndiratta 2015). Limited studies have sug-
gested that plasma exchange is not significantly different from IVIg
in efficacy (Dyck 1994), and that IVIg is not significantly different
from oral prednisolone (Hughes 2001). A six-month trial found
no significant difference in the outcomes between IVIg and in-
travenous methylprednisolone (Nobile-Orazio 2012). These two
trials are included in the Cochrane review of IVIg for CIDP
(Eftimov 2013). Many different immunosuppressive agents have
been tried and reported in case studies and case series; azathio-
prine, methotrexate, and beta-interferon have been tested in small
RCTs, but none have been shown to be efficacious (Mahdi-Rogers
2010).
How the intervention might work
Corticosteroids are widely used in medicine as anti-inflammatory
agents. They are lipid soluble so that they can easily cross the
cell membrane and engage the glucocorticoid receptor in the cy-
toplasm. The corticosteroid-receptor complex translocates to the
nucleus and modifies the transcription of genes, resulting in inhi-
bition of inflammatory mediator release, increase of anti-inflam-
matory molecules and reduction of circulating T-lymphocytes. In
high doses there are also more rapidly acting non-genomic effects
on membrane lipids and cytoplasmic proteins which also have an
anti-inflammatory effect (Strehl 2013).
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Why it is important to do this review
In view of the lack of evidence of efficacy for cytotoxic and im-
munomodulatory drugs in CIDP, and the expense and inconve-
nience of IVIg and plasma exchange, it is important to know the
strength of the evidence for corticosteroids, which are commonly
recommended as first line treatment. This is an update of a review
first published in 2001; the previous update was in 2015.
O B J E C T I V E S
To assess the effects of corticosteroid treatment for CIDP com-
pared to placebo or no treatment, and to compare the efficacy of
different corticosteroid regimens.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We searched for all RCTs or quasi-RCTs involving any form of
corticosteroid or adrenocorticotrophic hormone for the treatment
of CIDP. Quasi-RCTs are studies in which treatment allocation
is organised in a way which is intended to have the effect of ran-
domisation but which might nevertheless be biased (e.g. alternate
allocation).
Types of participants
We included trials in which the study authors had diagnosed par-
ticipants as having CIDP according to the probable or definite cri-
teria of the European Federation of Neurological Societies/Periph-
eral Nerve Society (EFNS/PNS) (Van den Bergh 2010). Partici-
pants must have had symptoms and signs of peripheral neuropa-
thy characterised by progressive or relapsing motor and sensory
dysfunction of more than one limb, and of more than eight weeks’
duration. An electrophysiological diagnosis of demyelinating neu-
ropathy based on reduced nerve conduction velocities or partial
conduction blocks must have confirmed the clinical diagnosis.
The diagnosis might have been confirmed by finding a raised cere-
brospinal fluid (CSF) protein or the demonstration of inflamma-
tion and macrophage-associated demyelination in a nerve biopsy,
but we did not consider these mandatory. We excluded partici-
pants with clinical features or investigations suggestive of heredi-
tary neuropathy, relevant systemic disease, or paraproteinaemia.
Types of interventions
We included treatment with any form of corticosteroid or adreno-
corticotrophic hormone compared with either placebo or no treat-
ment, and comparisons of different corticosteroid regimens. We
did not include comparisons of corticosteroids with other treat-
ments.
Types of outcome measures
Primary outcomes
Change in disability, measured by a validated scale such as the In-
flammatory Neuropathy Cause and Treatment (INCAT) disabil-
ity scale (Hughes 2001), Overall Disability Status Scale (ODSS)
(Merkies 2002), Overall Neuropathy Limitations Scale (ONLS)
(Graham 2006) or Rasch-built Overall Disability Scale (R-ODS)
(Van Nes 2011) after one year.
Secondary outcomes
1. Change in impairment after three months and one year,
measured by a validated scale such as the Mayo Neuropathy
Impairment Scale (NIS) (Dyck 1980), Medical Research
Council (MRC) Sum Score (Merkies 2006), or grip strength
(Merkies 2000).
2. Side effects of corticosteroids for as long as data allowed.
We intended to record all reported side effects, including
development of diabetes mellitus, infection requiring the use of
antibiotics, hypertension requiring treatment, hip fracture,
peptic ulcer, gastrointestinal haemorrhage, depression, psychosis,
cataract, and change in appearance (hair loss, facial hirsutism,
weight loss, and weight redistribution).
Search methods for identification of studies
Electronic searches
We modified the search strategy for this update to make it more
specific. On 8November 2016, we searched the Cochrane Neuro-
muscular Specialised Register, Cochrane Central Register of Con-
trolled Trials (CENTRAL, 8 November 2016 in the Cochrane
Register of Studies Online), MEDLINE (January 1966 to Novem-
ber 2016), and Embase (January 1980 to November 2016).
See Appendix 1 (Cochrane Neuromuscular Specialised Regis-
ter), Appendix 2 (CENTRAL), Appendix 3 (MEDLINE), and
Appendix 4 (Embase).
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Searching other resources
We also consulted disease experts and on 28 November 2016
searchedUSNational Institutes of HealthOngoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov), World Health Organi-
zation International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/en/) (Appendix 5), and references in reviews
and case series of CIDP.
Data collection and analysis
Two review authors (RACH and MMM) checked titles and ab-
stracts identified in the literature searches. We obtained the full
text of potentially includable studies for independent assessment
by both authors. Two authors (RACH andMMM) assessed risk of
bias according to the method proposed in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
We reported dichotomous data as a risk ratio (RR) and continuous
data as a mean difference (MD), each with corresponding 95%
confidence intervals (CI).
If we had found more than one trial investigating a particular
intervention, we would have calculated a weighted treatment ef-
fect (initially using a fixed-effect model) across trials using the
Cochrane statistical package, Review Manager 5 (RevMan 2014).
R E S U L T S
Description of studies
Results of the search
We found 30 (3 new) potentially relevant references in the
Cochrane Neuromuscular Specialised Register, 29 (8 new) in
CENTRAL, 238 (22 new) in MEDLINE and 168 (20 new) in
Embase. Of the 55 new references, 7 were already listed in the
previous version of the review and the Information Specialist re-
moved 13 by deduplication (Figure 1). None of the remaining 35
references were RCTs eligible for inclusion. Figure 2 is a PRISMA
flow chart illustrating the study selection process.
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Figure 1. Study flow diagram.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each included
study. Red (-) = high risk of bias; green (-) = low risk of bias; yellow (?) (not shown) = unclear risk of bias.
The results of the searches of DARE (one paper), NHSEED (two
papers) and HTA database (one paper), produced no additional
relevant references and there were none in ClinicalTrials.gov or
ICTRP. We found no additional RCTs in the bibliographies of
reviews but we have included some additional case series in the
Discussion.
Included studies
Only two studies fulfilled the criteria for this review, one com-
paring corticosteroids with placebo or no treatment (Dyck 1982),
and another comparing two different corticosteroid regimens
(PREDICT 2010). An additional trial comparing intravenous
methylprednisolone with intravenous immunoglobulin (Nobile-
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Orazio 2012) did not fulfil the inclusion criteria for this review
and has been considered in another Cochrane Review (Eftimov
2013).
Comparison of oral prednisone with no treatment
Dyck 1982 compared corticosteroids to no treatment, but did not
compare corticosteroids to placebo. The trial recruited 40 par-
ticipants over 58 months, and assigned them alternately to pred-
nisone or no treatment. Five participants were removed (three in
the treated group, and two from the control group) because of
misdiagnosis. A further seven (five in the treatment group, and
two in the control group) did not complete the study. Of the
five assigned to prednisone and excluded, one died from cardiac
arrhythmia, possibly related to hyperglycaemia, three had their
prednisone dosage altered from that allowed by the schedule, and
one remained dependent on a respirator and did not complete
follow-up. Two participants in the control group worsened and
were started on prednisone by their referring physicians because of
deterioration in their neurological status. Of the 28 participants
completing the trial, 14 participants belonged to each group (see
Characteristics of included studies). The treatment group started
on prednisone at a dosage of 120 mg every other day, tapered to
0 mg by the end of 12 weeks. The participants in the two groups
were well matched for age, sex, initial neurology disability score,
muscle strength, cutaneous sensation, nerve conduction values,
and CSF protein. The prednisone group included seven partici-
pants with a progressive course and seven with a recurrent course.
The untreated group comprised 12 participants with a progressive
course and two with a recurrent course.
Comparison of high-dose monthly oral
dexamethasone with standard-dose daily oral
prednisolone
One parallel group, double-blind RCT with 41 participants com-
pared twodifferent oral corticosteroid regimens (PREDICT 2010)
(see Characteristics of included studies). One group received six
cycles of dexamethasone 40 mg daily for four days, followed by
placebo for 24 days. The other group received prednisolone for 32
weeks, starting with 60 mg daily for five weeks and then gradually
tapering to zero by the 32nd week.
Risk of bias in included studies
Comparison of oral prednisone with no treatment
In Dyck 1982, treatment allocation was randomised for the first
person in each pair of participants, but the second person re-
ceived the alternative treatment, which was supportive care with-
out steroids. There was no placebo, so randomisation was not con-
cealed from the participant. The report does not state whether
allocation was concealed from the investigator, or whether follow-
up assessments were blinded. The numbers of participants ran-
domised, withdrawn, and not completing treatment were available
and the analysis took into account baseline characteristics. In view
of the lack of allocation concealment and blinding, we considered
this trial to have a high risk of bias (See Characteristics of included
studies; Figure 2).
Comparison of high-dose monthly oral
dexamethasone with standard-dose daily oral
prednisolone
PREDICT 2010 had a low risk of bias since randomisation was
performed, allocation was carefully concealed, and trial medica-
tion was identical in appearance in both groups (Characteristics
of included studies; Figure 2).
Effects of interventions
See: Summary of findings for the main comparison Prednisone
for chronic inflammatory demyelinating polyradiculoneuropathy;
Summary of findings 2 Monthly
pulsed high-dose dexamethasone compared to oral prednisolone
for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison of oral prednisone with no treatment
Data for our primary outcome measure, change in disability, were
not available for this comparison, but the trial provided data for
our secondary outcomemeasure, change in impairment after three
months. In their own analysis, the authors of Dyck 1982 omitted
seven participants who breached their protocol, and reported the
results for the remainder. The median score at baseline was 74
NIS points in both groups, with the lowest values being 28, and
the highest 137. A healthy person would score zero, with higher
values indicating more impairment, with the worst possible score
being 280 (the scale is non-linear). After 12 weeks, there was a
median deterioration in the NIS score of 1.5 points in the un-
treated group and an improvement in the prednisone group of 10
points, giving a significant result (P = 0.016) (data directly from
paper). We were concerned that omission of the seven participants
biased the results in favour of prednisone treatment. We repeated
their calculations, including the participants who breached proto-
col and had been excluded, so as to perform a true intention-to-
treat (ITT) analysis. When we imputed the worst value for each
group for the missing values, the results still favoured prednisone
treatment (median increase (worsening) of two points in the con-
trol, and decrease (improvement) of five points in the prednisone
group), but the difference was not statistically significant. We also
calculated the mean improvement in impairment and 95% CI
when the seven withdrawn participants were excluded, leaving 28
participants (MD 17.14, 95% CI -4.39 to 38.67), or when they
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were included with the assumption that they had not improved
(MD 11.60, 95% CI -9.39 to 32.58) (Analysis 1.1; Analysis 1.2;
Summary of findings for themain comparison). Although both ef-
fect estimates suggested that prednisone may be of clinical benefit,
we consider the effects uncertain because vulnerable to the effects
of missing data, other risks of bias, and imprecision, with wide CI
that encompassed benefit and potential harm; the evidence was
very low quality.
An alternative method of looking at this outcome, albeit not one
which we had stipulated in our protocol, was to compare the pro-
portions of participants who had improved, stayed the same, or
worsened after 12 weeks. When this analysis was done omitting
the seven participants who breached protocol (i.e. in 28 partici-
pants), five participants showed spontaneous improvement, one
remained the same, and eight worsened in the control group. On
the other hand, in the treatment group, 12 participants improved
from their initial impairment score, while two worsened. These
proportions favoured prednisone (RR 2.40, 95% CI 1.15 to 5.00;
very low-quality evidence; Analysis 1.3; Summary of findings for
the main comparison). When we repeated this analysis on all 35
participants, categorising the seven who were withdrawn as not
having improved, the result still favoured prednisone, but the ef-
fect was slightly smaller and the lower CI encompassed the pos-
sibility of no effect; the RR for improvement was 2.02 (95% CI
0.90 to 4.52; very low-quality evidence; Analysis 1.4; Summary of
findings for themain comparison). Othermeasures of impairment
reported by the investigators in the 28 participants who were fol-
lowed up: touch-pressure threshold on the hand (P = 0.017) and
grip strength (P = 0.046), showed significantly more improvement
in the prednisone-treated group than the untreated group. These
measures were not available for those who were withdrawn and so
an ITT analysis was not possible.
The only reported side effect related to treatment was the occur-
rence of hyperglycaemia in one participant treatedwith prednisone
who was withdrawn.
Outcomes reported but not included in our predefined
outcome measures
Data were also available for electrophysiological outcome mea-
sures. Amplitudes, conduction velocities, and latencies of motor
fibres of ulnar, median, and peroneal nerves as well as amplitudes
and distal latencies of digital nerve action potentials of the me-
dian and ulnar nerves were obtained at onset and at three months.
The following variables showed significant improvement in the
prednisone compared to the control group: median (P = 0.029)
and peroneal (P = 0.056) motor nerve conduction velocity and
median nerve compound muscle action potential amplitude (P =
0.056). The data on these parameters were not available for those
participants who did not complete the protocol.
Comparison of high-dose monthly oral
dexamethasone with standard-dose daily oral
prednisolone
PREDICT 2010 did not report the outcomes preselected for this
review, but did report meaningful outcomes. The primary out-
come defined by the trial authors was reaching and remaining in
remission without treatment at 12months. Remission was defined
as a minimum of three points improvement on the RMI and min-
imum of one point improvement in the INCAT disability scale.
If a participant did not show improvement or disease stabilisation
compared with baseline at eight weeks, or relapsed or had serious
side effects, trial treatment was stopped and this was considered a
treatment failure.
Forty-one people were randomly assigned. After one day of trial
assignment, one person, who had not by then received any treat-
ment, withdrewbecause of rapid progression in disease and change
in diagnosis. Twenty-four participants were assigned to dexam-
ethasone and 16 to prednisolone. The dexamethasone and pred-
nisolone groups were well matched at baseline. Eighteen men and
six women were randomised to dexamethasone and 10 men and
six women to prednisolone. The mean (range) age was 59.9 (25.8
to 80.2) years in the dexamethasone group and 60.8 (25.3 to 87.7)
years in the prednisolone group. The mean (interquartile range)
disease duration was 13.5 (5.3 to 28.5) months in the dexam-
ethasone group and 8.5 (6.0 to 15.0) months in the prednisolone
group.
In the analysis of the trial authors’ primary outcome, 10 out of
24 in the dexamethasone group and six out of 16 in the pred-
nisolone group achieved remission at the end of one year, a differ-
ence slightly in favour of dexamethasone, but with wide CI that
included the possibility of clinically relevant differences in either
direction (RR 1.11; 95% CI 0.50 to 2.45; moderate-quality evi-
dence; Analysis 2.1; Summary of findings 2). Seven of 24 partic-
ipants in the dexamethasone and eight of 16 participants in the
prednisolone group deteriorated. There were no significant differ-
ences between the groups in any of the secondary outcomes mea-
sured by the authors, including change at endpoint in MRC sum
score (Analysis 2.3; low-quality evidence), grip strength (Analysis
2.4; moderate-quality evidence), disability scale, INCAT sensory
sum score (low-quality evidence), or Short Form-36Health Survey
quality of life scores. The endpoint was 12 months or premature
cessation of treatment if after eight weeks if there had been wors-
ening or no stabilisation, or if there was a relapse back to baseline
state, or if there were serious side-effects due to the drug. There
was a suggestion that improvement was faster in the dexametha-
sone treated group; median time to remission was 20 weeks (95%
CI 12.4 to 27.6) in the dexamethasone group in comparison to
39 weeks (95% CI 29.9 to 48.1) in the prednisolone group (P =
0.057). Median time to improvement by one point in the INCAT
disability scale was 17 weeks (95% CI 13.8 to 20.2) in the dexam-
ethasone group and 39 weeks (29.9 to 48.1) in the prednisolone
group (P = 0.036).
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Side effects, including diabetes mellitus, hypertension, and os-
teopenia, were comparably common in both groups, with the ex-
ception of sleeplessness and cushingoid facies, which were more
common in the daily prednisolone group (RR 0.44, 0.24 to 0.84
and RR 0.50, 0.21 to 1.17, respectively; low- and moderate-qual-
ity evidence) (Analysis 2.5; Analysis 2.6; Summary of findings 2).
Severe weight gain (> 3 kg) was more common with daily pred-
nisolone than with dexamathasone (RR 0.11, 95% CI 0.01 to
0.84) but weight gain of 1 kg to 3 kg was not, although this result
was somewhat imprecise (RR0.96, 95%CI 0.55 to 1.70) (Analysis
2.7; Analysis 2.8). One participant in the dexamethasone group
developed acute glaucoma after one cycle and stopped treatment.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Monthly pulsed high-dose dexamethasone compared to oral prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
Patient or population: people with chronic inf lammatory demyelinat ing polyradiculoneuropathy
Settings: hospital specialist neurological outpat ient department
Intervention: monthly pulsed high-dose dexamethasone
Comparison: oral prednisolone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk or value Corresponding risk or
value
Oral prednisolone Monthly pulsed high-
dose dexamethasone
Change in disability af-
ter one year
- - - - - Not measured
Remission at 12
months
375 per 1000 416 per 1000
(188 to 919)
RR 1.11
(CI 0.5 to 2.45)
40
(1 RCT)
⊕⊕⊕©
Moderate1
Not signif icant
≥ 1 point improve-
ment on INCAT disabil-
ity score at 12 months
438 per 1000 542 per 1000
(280 to 1000)
RR 1.24
(CI 0.64 to 2.41)
40
(1 RCT)
⊕⊕©©
Low 2
Not signif icant
Change in impairment:
change in MRC sum
score at endpoint4
The mean change in the
oral prednisolone group
was a 1.6 (SD 6.84)
point increase
The mean change in
MRC sum score with
monthly high-dose dex-
amethasone was
2.4 higher (1.9 lower to
6.7 higher)
- 39
(1 RCT)
⊕⊕©©3
Low
Not signif icant
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Change in impairment:
change in grip strength
at endpoint4
The mean change in the
oral prednisolone group
was a 13.4 (SD 38.53)
kPa increase
The mean change in
grip strength with
monthly high-dose dex-
amethasone was
5.3 kPa lower (28.43
lower to 17.83 higher)
- 38
(1 RCT)
⊕⊕⊕©
Moderate5
Not signif icant
Sleeplessness 750 per 1000 330 per 1000
(180 to 630)
RR 0.44
(CI 0.24 to 0.84)
40
(1 RCT)
⊕⊕©©6Low Signif icant ly less with
monthly high-dose dex-
amethasone
Moon facies 688 per 1000 330 per 1000
(172 to 639)
RR 0.48
(CI 0.25 to 0.93)
40
(1 RCT)
⊕⊕⊕©7
Moderate
Signif icant ly less with
monthly high-dose dex-
amethasone
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; INCAT : Inf lammatory Neuropathy Cause and Treatment; MRC: Medical Research Council; RR: risk rat io; SD: standard deviat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded by one, for imprecision. The data are f rom a single study, which did not achieve planned recruitment, had a
small sample size and 95%CI are wide.
2Downgraded twice, for imprecision and indirectness. The data are f rom a single study, which did not achieve planned
recruitment, had a small sample size and 95%CI are wide. The INCAT score is not a linear scale.
3Downgraded twice, for imprecision and indirectness. The data are f rom a single study, which did not achieve planned
recruitment, had a small sample size and 95%CI are wide; also, the MRC sum is not a linear scale.
4The endpoint was 12 months or premature cessat ion of treatment if af ter 8 weeks if there had been worsening or no
stabilisat ion, or if there was a relapse back to baseline state, or if there were serious side-ef fects due to the drug.
5Downgraded by one for imprecision. The data are f rom a single study, which did not achieve planned recruitment, had a
small sample size and 95% CI are wide (imprecision). Grip strength is a linear and direct measure so we did not downgraded
a second t ime.
6Downgraded twice, for serious imprecision and indirectness. The data are f rom a single study, which did not achieve planned
recruitment, had a small sample size and 95%CI are wide. Sleeplessness is a subject ive outcome caused by many factors.
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7Downgraded by one for imprecision. The data are f rom a single study, which did not achieve planned recruitment, had a small
sample size and 95% CI are wide.
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D I S C U S S I O N
Comparison of corticosteroids with no
treatment
Summary of the main results and quality of the
evidence
The Dyck 1982 trial comparing prednisone for 12 weeks with
no treatment was a pioneering study in the field of inflammatory
neuropathy. By modern standards the trial had a high risk of bias
because of failure to conceal allocation, absence of blinding, and
lack of ITT analysis. Additionally, the sample size was small, the
outcome measures non-linear and compound, and the result im-
precise. The trial authors concluded that corticosteroids signifi-
cantly reduced impairment and improved measures of nerve con-
duction. There was no information concerning disability, our pre-
ferred primary outcome measure. When we imputed pessimistic
values for the participants who were withdrawn and re-analysed,
the results for one of our secondary outcome measures, improve-
ment in impairment 12 weeks after randomisation, favoured cor-
ticosteroids, but the quality of evidence was very low (Summary of
findings for the main comparison). The interpretation of the re-
sults of the trial is critically dependent on how the withdrawn par-
ticipants are analysed.Onewithdrawnprednisone participant died
and another remained ventilated, which favours no prednisone.
Two withdrawn control participants worsened and then improved
on prednisone, which favours prednisone. In the study authors’
own analysis, excluding the seven participants who breached pro-
tocol, there was significant improvement in measures of sensory
threshold, grip strength and nerve conduction. The absence of a
true ITT analysis seriously weakens the strength of the evidence
that corticosteroids are beneficial.
Overall completeness and applicability of the
evidence
There have been no trials comparing corticosteroids with placebo
in CIDP. Since there is so little evidence from randomised stud-
ies, we also considered large series in which the use of corticos-
teroids has been reported. In 1958, Austin described recurrent
steroid-responsiveness in two people and reviewed nine others
(Austin 1958). In one, Austin demonstrated steroid-responsive-
ness through documentation of 20 recurrences over a five-year
period compared with significant progression following oral, in-
tramuscular, and intravenous placebo administration. Others re-
ported benefit from corticosteroids in single cases or small case
series (DeVivo 1970; Thomas 1969).
Dalakas 1981 reported 25 people with CIDP treated with corti-
costeroids alone in an observational study in which “the majority”
improved. The study authors emphasised that a lag period, usually
of one to four weeks, but occasionally up to five months, occurred
from onset of therapy to the first sign of improvement. They rec-
ommended high doses of steroids for about one year, then cautious
tapering to avoid pharmacorelapses, and long-term, low, mainte-
nance doses to prevent spontaneous relapses. Beneficial effects of
corticosteroids have also been documented in children with CIDP
(Hattori 1998; Nevo 1996; Simmons 1997; Sladky 1986).
McCombe 1987 reported a study of 92 cases of all ages. Sixty
(65%) participants had a relapsing course and 32 participants
(35%) a progressive or monophasic course. Seventy-six partici-
pants were treated with corticosteroids. Forty-nine participants
(65%) made a good recovery and were independent. Similarly,
Barohn 1989 studied 60 people aged 10 to 77 years. A consistent
approach to treatment was used over the decade of observation.
Participants were started on a regimen of 100 mg of prednisone
daily for two to four weeks and then switched to prednisone 100
mg in a single dose on alternate days. This regimen was continued
until clinical improvement plateaued. If the participant’s response
was poor or a relapse occurred, either azathioprine or plasma ex-
change was added to the treatment. Fifty-six (94.9%) of 59 treated
participants showed initial improvementwith immunosuppressive
treatment. The mean (standard deviation (SD)) time for improve-
ment was 1.9 (3.6) months. The mean time to reach a clinical
plateau was 6.6 (5.4) months. In an abstract, Machkhas 1997 re-
ported benefit from pulsed intravenous methylprednisolone 1000
mg daily for five days and then 1000 mg daily every one to four
weeks in five people with CIDP. Side effects were not reported.
Sabatelli 2001 reported that four people with pure motor CIDP
did not respond to prednisolone but all four responded to IVIg.
Particularly helpful is the detailed, albeit retrospective, Italian na-
tional study which included 136 people with CIDP treated with
corticosteroids as first line therapy, of whom 51% responded with
a one or more point improvement in the Rankin score and 19 of
whom (12.5%) had side effects (five people with diabetes melli-
tus, four with hypertension, three with osteoporosis, three with
duodenal ulcer, two with psychosis, and one with obesity) (Cocito
2010). Fourteenparticipantswhohadpreviously been treatedwith
IVIg were switched to corticosteroids, and six (43%) responded.
This large systematic national survey suggests that corticosteroids
induce at least short-term improvement in about half of people
with CIDP, less than the 65% or more suggested by smaller case
series studies from single centres. It also documents the improve-
ment of some people on corticosteroids after switching from IVIg,
which has been noted before (Pedersen 2007).
Care must be exercised in starting treatment because some peo-
ple with CIDP deteriorate, as reported in case series (Dyck 1975;
Rostasy 2003) and PREDICT 2010. In a post hoc analysis of
PREDICT 2010, seven of 33 participants deteriorated within
eight weeks after start of treatment, four patients had received dex-
amethasone and three had received prednisolone (Eftimov 2014).
There is no known method for identifying people with CIDP who
will deteriorate. Deterioration has been considered more likely in
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pure motor CIDP (Donaghy 1994), but also occurs in pure sen-
sory CIDP (Chroni 2015; Rajabally 2012). The likelihood of re-
sponse to steroids in various atypical forms of CIDP is also un-
certain. A retrospective review of published accounts of multifocal
asymmetric upper limb-onset CIDP found that 52% of people
(14 of 27) treated with steroids improved compared to 74% (31 of
42) of those treated with IVIg. The same review found that people
with multifocal asymmetric lower limb-onset forms were signifi-
cantly less likely to respond to steroids than IVIg (2 of 8 (25%)
versus 14 of 16 (87%)) (Rajabally 2009). According to a retrospec-
tive study of seven people with corticosteroid-responsive disease
and seven who were non-responsive to corticosteroid, corticos-
teroid response was significantly more likely in those with smaller
sensory action potentials and longer upper limb F wave latencies
(Rajabally 2008). In a retrospective study of 50 people with CIDP
(Chan 2006), there was no difference in responsiveness to any im-
munotherapy (including IVIg, as well as corticosteroids) between
27 people with neurophysiologically definite and 23 people with
neurophysiologically probable CIDP, classified according to the
INCATcriteria (Hughes 2001). Five out of seven people with early
deterioration had a focal distribution pattern of demyelination,
compared to only five out of 26 people without early deterioration
(P = 0.02) (Eftimov 2014). This observation suggests that a focal
pattern of demyelination might predict worsening after starting
corticosteroids. but this requires confirmation in new prospective
studies. The mechanism by which corticosteroids can cause wors-
ening is not known. Eftimov 2014 speculated that corticosteroids
might upregulate the axonal Na+K+ pump, causing hyperpolari-
sation and conduction block, especially in motor nerve fibres.
The issue of side effects is very important in deciding whether to
use corticosteroids as the first line treatment for CIDP (Bromberg
2004). Side effects include weight gain, hirsutism, cushingoid or
moon facies, susceptibility to overwhelming infection, osteoporo-
sis, hip fracture, hypertension, diabetes mellitus, cataracts, pep-
tic ulcer, gastrointestinal haemorrhage, and psychiatric manifesta-
tions (Goodman 1996), many of which have been reported in the
case series studies described in the discussion above. Many of these
effects are not adequately captured in short-term trials, even those
with follow-up for one year, but are relevant when considering the
value of long-term treatment.
Cost is another important consideration. Oral prednisone or pred-
nisolone are cheap to purchase but monitoring for the known side
effects incurs costs, and the long-term costs of serious side effects
are substantial. However, even when these are taken into account,
corticosteroids are much less expensive than the main alternative,
IVIg (Blackhouse 2010; McCrone 2003).
Comparison of different corticosteroid regimens
Summary of the main results and quality of the
evidence
One trial compared a commonly-used regimen of standard-dose
daily oral prednisolone with monthly, high-dose, oral dexametha-
sone (PREDICT 2010). There was probably little or no differ-
ence between regimens in the primary outcome chosen by the
trial authors (remission after 12 months). Monthly dexametha-
sone produced a more rapid one point INCAT improvement than
oral prednisolone, which reached statistical significance. Unex-
pectedly, one-third of the participants deteriorated, slightly but
not significantly more in the daily prednisolone group. Minor side
effects were common, and sleeplessness (low-quality evidence) and
cushingoid facies (moderate-quality evidence) weremore common
in the prednisolone group. Weight gain of more than 3 kg was
more common in the prednisolone group both during treatment
and follow-up periods. The trial had a low risk of bias. The limita-
tions of this evidence, which we judged to be of low to moderate
quality for efficacy, are that there was only one trial, the sample size
was smaller than intended because of the slow recruitment rate,
and some measures were imprecise and also to an extent indirect
(Summary of findings 2).
The trial included an informal follow-up after a median 4.5 years
when data were available from 39 of 40 participants (Eftimov
2011; Eftimov 2012). Cure (off treatment > five years) or remis-
sion (off treatment > five years) occurred in seven out of 24 partic-
ipants initially treated with pulsed dexamethasone and six out of
16 participants initially treated with prednisolone. Half those in
remission after initial treatment relapsed. The median treatment-
free interval was longer, 17.5 months, for pulsed dexamethasone
than for conventional dose prednisolone (11 months), which was
not a clear difference. Unfortunately, the different treatments re-
ceived after the end of the one-year trial confounded these com-
parisons. Importantly, the diagnosis turned out to be wrong in
seven participants, who accounted for more than half of the 12
who did not respond to any treatment.
Overall completeness and applicability of the
evidence
There have beenmany case reports, case series studies, and reviews
describing widely varying types, doses and routes of corticosteroid
usage in CIDP (Bromberg 2004), but no other RCTs. PREDICT
2010 was based on an observational study of six cycles of oral dex-
amethasone 40 mg daily for four days every four weeks, in which
six of ten participants went into remission (Molenaar 1997). A
retrospective observational study of 39 participants (out of 57with
available records), included 16 participants who received intermit-
tent intravenous methylprednisolone 1000 mg daily for three to
five days and then 1000 mg monthly, seven who received IVIg,
and 16 people who received oral treatment consisting of either
prednisone (in 12) or ciclosporin (in four) (Lopate 2005). After six
months, the average improvement in muscle strength was similar
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in all three groups. Cushingoid appearance and weight gain were
more common in those who received oral prednisone. Kuwabara
2006 treated 38 people withCIDPof whom33 received high-dose
corticosteroids as their first treatment: of these 33, 70% improved
by one or more points on the seven-point GBS disability grade
scale by two months. Some people were subsequently treated with
IVIg or plasma exchange so that their five-year status cannot be
attributed solely to corticosteroids, but 26% were in complete re-
mission off treatment, 29% were still being treated with corticos-
teroids, 10% needed aid to walk, and one had died of complica-
tions associated with tetraplegia. Side effects were not mentioned.
In another retrospective observational study, Muley 2008 treated
10 people with oral methylprednisolone 500 mg once a week for
three months, and the dose was adjusted every three months by 50
mg to 100 mg depending on clinical status. One person stopped
treatment after two days because of duodenal ulceration, but six
of the remaining nine entered and maintained treatment-free re-
mission after a mean of 27 (SD 7.04) months. Long-term skin
thinning and cushingoid facies were each reported in three people,
and five people developed osteoporosis.
Boru 2014 treated 20 people with CIDPwith intravenous methyl-
prednisolone 1000mg/day for 10 days and then 1000mgmonthly
for five years. Five people were not followed up, one because of
lack of response, another because of nausea and hypertension, and
three for reasons unrelated to the study. The remaining 15 all
improved compared with baseline by at least one point on the
modified Rankin score at the first and fifth year. After five years,
treatment was stopped and during a five further years’ follow-up,
six participants relapsed. All those relapsing received intravenous
methylprednisolone again and three responded. Side-effects oc-
curred in nearly half the participants, including weight gain in six,
but no other participants had to stop treatment.
The inclusion criteria for this review did not allow us to consider
RCTs comparing corticosteroids with IVIg or other treatments
(Hughes 2001; Nobile-Orazio 2012). These have been considered
in the Eftimov 2013 Cochrane review and the Oaklander 2017
Cochrane overview.
Comparison of corticosteroids with no
treatment and comparison of different
corticosteroid regimens
Potential biases in the review process
For both the comparisons included in this review, we are confident
that we have identified all RCTs comparing corticosteroids with
placebo or no treatment and comparing different corticosteroid
regimens. However, the exclusion of comparisons with other treat-
ments especially IVIg is a limitation which has been corrected by
their inclusion in other reviews (Eftimov 2013; Oaklander 2017).
We also recognise that it is not possible to identify all the non-
randomised evidence. Our review of published case series may not
be complete, and will have been limited by the impossibility of
including all treated and untreated people with CIDP. Of con-
cern is that one of the RCTs identified only considered 12 weeks
of treatment, and the other only 12 months, whereas in practice,
people with CIDP may require treatment for years. Longer RCTs
of corticosteroids are unlikely to be done.
Agreements and disagreements with other studies or
reviews
There have been no other systematic reviews. The conclusions of
this review are in line with the assessment of the evidence by an
international expert panel (Van den Bergh 2010). A more recent
non-systematic review including the comparison of corticosteroids
with IVIg supports the use of pulsed high-dose corticosteroids
rather than IVIg as the first treatment choice in people with non-
motor-dominant CIDP who are not extremely disabled (Press
2016). Two other Cochrane reviews consider the comparison of
corticosteroids with IVIg (Eftimov 2013; Oaklander 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are very uncertain about the effects of prednisone in com-
parison to no treatment in chronic inflammatory demyelinating
polyradiculoneuropathy as the quality of evidence is very low.
Nevertheless, corticosteroids are commonly used in practice, sup-
ported by very low-quality evidence from observational studies
and apparent clinical efficacy in day-to-day use. Corticosteroids
are known from observational studies to carry the long-term risk
of serious side effects. High-dose monthly oral dexamethasone
probably has similar efficacy to daily oral prednisolone. Both cause
short-term side effects, but sleeplessness may be less common and
moon facies is probably less common with monthly dexametha-
sone.
Implications for research
Further research is needed to identify factors which predict re-
sponse and deterioration after corticosteroids. Randomised con-
trolled trials are urgently needed to discover whether corticos-
teroids are cost effective compared with other treatments, espe-
cially intravenous immunoglobulin, and whether adjunctive treat-
ment with immunosuppressive agents is superior to corticosteroids
alone.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dyck 1982
Methods Parallel group, unblinded quasi-RCT
Single centre
Participants 28 people with CIDP according to criteria similar to those of Van den Bergh 2010
Prednisone group n = 14 (10 M and 4 F), median age 46.5 years in the prednisone
No steroid control group n = 14 (9 M and 5 F), median age 50 years. See notes
Interventions Prednisone 120 mg every other day tapered to 0 mg in 12 weeks, versus no treatment
Outcomes • Primary: change in impairment (Neurology Disability Score)
• Secondary: change in maximum motor nerve conduction velocity and compound
muscle action potential after 12 weeks. When more than one nerve was tested, the
average of all the nerves was used
Side effects
Notes 5 participants from an original 40 were removed because of misdiagnosis
7 participants did not complete the study as described in the ’Risk of bias’ table support
for judgement
Supported by grants from theNational Institutes of Communicable Diseases and Stroke,
the Muscular Dystrophy Asociation and the Mayo, Borchard, Upton and Gallagher
funds
No conflicts of interest declared
Dates of study not stated but recruitment took 58 months
Conducted in the USA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk People with CIDP who fulfilled the de-
scribed criteria were matched for age (18
to 29 years, 30 to 59 years, and over 60
years) and duration from onset of symp-
toms (6 months to 1.9 years, 2 to 3.9 years,
and over 4 years). Male and female par-
ticipants were randomly assigned to treat-
ment or no treatment. In practice, the first
participant in each age-duration-sex group
was randomly assigned to prednisone or no
treatment. The second participant in each
group received the alternate therapy, fol-
lowed by random assignment to the third
participant, and so on
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Dyck 1982 (Continued)
Allocation concealment (selection bias) High risk People with CIDP who fulfilled the de-
scribed criteria were matched for age (18 to
29 years, 30 to 59 years, and over 60 years)
and duration from onset of symptoms (6
months to 1.9 years, 2 to 3.9 years, and
over 4 years). Male and female participants
were randomly assigned to treatment or no
treatment. In practice, the 1st participant
in each age-duration-sex group was ran-
domly assigned to prednisone or no treat-
ment. The 2nd participant in each group
received the alternate therapy, followed by
random assignment to the 3rd participant,
and so on
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comparison of prednisone with no treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comparison of prednisone with no treat-
ment
Incomplete outcome data (attrition bias)
All outcomes
High risk 7 participants did not complete the study
through protocol breaches and were not
included in the trial analysis. Of 5 pred-
nisone-treated participants, 1 died from
cardiac arrhythmia possibly related to
hyperglycaemia, 3 had their prednisone
dosage altered from that allowed by the
schedule, and 1 remained dependent on
a respirator at another medical centre and
could not return for follow-up. Two par-
ticipants in the control group were started
on prednisone therapy by their referring
physicians because of neurological worsen-
ing. Both were reported to have improved
Selective reporting (reporting bias) Low risk No selective reporting identified
Other bias Low risk No other risk of bias identified
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PREDICT 2010
Methods Multicentre, double-blind, parallel-group RCT
Participants 40 participants
Dexamethasone group (n = 24) (18 M and 6 F), mean age 59.9 years
Daily prednisolone group (n = 16) (10 M and 6 F) mean age 60.8 years
“Patients aged at least 18 years of age with newly diagnosed definite or probable CIDP
according to the European neuromuscular centre diagnostic criteria (Franssen 1997).
Patients had to have signs and symptoms sufficiently severe to warrant treatment and
had to be treatment naive. Exclusion criteria were other diseases known to cause neu-
ropathy (for example diabetes mellitus, paraproteinaemia (with the exception of an IgG
paraproteinaemia of undetermined significance), thyroid disease, vitamin B1 or B12 de-
ficiency, or significant haematological, renal, or liver disorders); diseases known to lead to
reduced mobility, severe handicap, or sudden death; contraindications to corticosteroid
therapy; use of drugs known to cause neuropathy; CSF cell count of more than 30 per
mm³; and premenopausal women not using a reliable means of contraception. Patients
with subacute inflammatory demyelinating polyneuropathy or motor CIDP (no sensory
signs or symptoms and no abnormalities in sensory nerve conduction studies) were also
excluded.”
Interventions “Either oral dexamethasone 40 mg per day for 4 days consecutively followed by placebo
for 24 days, repeated for six cycles, or daily prednisolone for 32 weeks starting with 60mg
per day for 5 weeks and tapering to alternate day doses and then to zero over the next 27
weeks......Patients on dexamethasone received a cumulative dose of 960 mg dexametha-
sone equivalent to 6400 mg prednisolone; patients in the prednisolone group received a
cumulative dose of 6425 mg prednisolone equivalent to 964 mg dexamethasone.”
Outcomes “The primary outcome was the percentage of patients who reached and remained in
remission without treatment at 12 months. Remission was defined as improvement of
at least three points on the RMI (Collen 1991) and improvement of at least one point
on the INCAT disability scale (Hughes 2001) compared with baseline or when the best
possible score of a scale had been reached. The RMI ranges from 0 (unable to mobilise)
to 15 (fully mobile); the INCAT disability scale ranges from 0 (healthy) to 10 (unable
to make any purposeful movements with arms or legs)”
“Secondary outcomes were time to reach remission, number of patients who relapsed
within 12months, time to relapse, number of patients who improved by at least one point
on the INCAT disability scale, number of patients who improved by at least three points
on the RMI, change in grip strength as assessed with a handheld dynamometer, change in
Medical Research Council sum score (range 0-60; including shoulder abduction, elbow
flexion, wrist extension, hip flexion, knee extension, and foot dorsiflexion), change in
INCAT sensory sum score, change in Short Form-36 Health Survey, and change in
ALDS: range 0 (dead) to 100 (fully able)”
Notes “All patients also received alendronate 10 mg daily or 70 mg weekly to prevent osteo-
porosis. Daily calcium 1000mg and vitamin Dwas added at the discretion of the treating
neurologist. After randomisation, patients were not allowed any other immunomodula-
tory or immunosuppressive treatment until they reached a predefined endpoint”
At each visit adverse events were recorded using a structured questionnaire. Body weight,
blood pressure, bone densitometry and eye examination were done at baseline and at
endpoint
Funded by the Prinses Beatrix Fonds and the Department of Neurology, Academic
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PREDICT 2010 (Continued)
Medical Center
No conflicts of interest declared.
Recruitment stopped on 1 December 2007 when 41 of the desired 52 participants had
been recruited and final follow-up was on 1 December 2008
Conducted in 8 neuromuscular centres in the Netherlands and one in the UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial pharmacist, who had no further
role in the study, randomised each partic-
ipant on inclusion. Treatment allocation
was performed in a 1:1 ratio by use of a
randomnumber generator. Aminimisation
procedure was used for age (< 50 and≥ 50
years)
Allocation concealment (selection bias) Low risk The trial pharmacist, who had no further
role in the study, randomised each partic-
ipant on inclusion, and treatment alloca-
tion was performed in a 1:1 ratio by use
of a random number generator. A minimi-
sation procedure was used for age (< 50
and ≥ 50 years). Dexamethasone, pred-
nisolone, and placebo came in identical
capsules. After randomisation, the pharma-
cist delivered trial drugs in identical white
blister packs with the participant’s iden-
tification number, week number, and day
number on the outside to the trial nurse,
who was masked to treatment allocation.
This process ensured concealment of treat-
ment before allocation. The trial nurse sent
the drugs to the various centres by courier.
Participants and assessors were unaware of
the treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Dexamethasone, prednisolone, and
placebo came in identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Dexamethasone, prednisolone, and
placebo came in identical capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 of the 41 participants withdrew on the
day after randomisation due to rapid pro-
gression and change of diagnosis
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PREDICT 2010 (Continued)
Selective reporting (reporting bias) Low risk No selective reporting identified
Other bias Unclear risk Trial stopped early before complete recruit-
ment because of difficulties with recruit-
ment
ALDS: Academic Medical Center Linear Disability Score
CIDP: chronic inflammatory demyelinating polyradiculoneuropathy
CSF: cerebrospinal fluid
F: female
IgG: immunoglobulin G
INCAT: Inflammatory Neuropathy Cause and Treatment
M: male
RCT: randomised controlled trial
RMI: Rivermead Mobility Index
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Lopate 2005 Non-randomised observational study
Nobile-Orazio 2012 Compared corticosteroids with intravenous immunoglobulin and not with placebo or no treatment. Included
in Eftimov 2013
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroids versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in impairment
after 12 weeks excluding those
who did not complete the study
1 28 Mean Difference (IV, Fixed, 95% CI) 17.14 [-4.39, 38.67]
2 Improvement in impairment
after 12 weeks including those
who did not complete the study
1 35 Mean Difference (IV, Fixed, 95% CI) 11.60 [-9.39, 32.58]
3 Number of patients improved
after 12 weeks excluding those
who did not complete the study
1 28 Risk Ratio (M-H, Fixed, 95% CI) 2.4 [1.15, 5.00]
4 Number of patients who showed
improvement after 12 weeks
including those who did not
complete the study
1 35 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.90, 4.52]
Comparison 2. Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Remission at 12 months 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.50, 2.45]
2 ≥ 1 point improvement on
INCAT disability score at 12
months
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.64, 2.41]
3 Change in MRC sum score at
endpoint
1 39 Mean Difference (IV, Fixed, 95% CI) 2.4 [-1.90, 6.70]
4 Change in grip strength at
endpoint
1 38 Mean Difference (IV, Fixed, 95% CI) -5.30 [-28.43, 17.
83]
5 Sleeplessness 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.24, 0.84]
6 Cushingoid facies 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.21, 1.17]
7 Weight gain 1 - 3 kg 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.55, 1.70]
8 Weight gain > 3 kg 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 0.84]
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Analysis 1.1. Comparison 1 Corticosteroids versus control, Outcome 1 Improvement in impairment after
12 weeks excluding those who did not complete the study.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 1 Corticosteroids versus control
Outcome: 1 Improvement in impairment after 12 weeks excluding those who did not complete the study
Study or subgroup Prednisone No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1982 14 20.64 (29.25) 14 3.5 (28.87) 100.0 % 17.14 [ -4.39, 38.67 ]
Total (95% CI) 14 14 100.0 % 17.14 [ -4.39, 38.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours no treatment Favours prednisone
Analysis 1.2. Comparison 1 Corticosteroids versus control, Outcome 2 Improvement in impairment after
12 weeks including those who did not complete the study.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 1 Corticosteroids versus control
Outcome: 2 Improvement in impairment after 12 weeks including those who did not complete the study
Study or subgroup Prednisone No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dyck 1982 19 9.15789 (31.74948) 16 -2.44 (31.3963) 100.0 % 11.60 [ -9.39, 32.58 ]
Total (95% CI) 19 16 100.0 % 11.60 [ -9.39, 32.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours no treatment Favours prednisone
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Analysis 1.3. Comparison 1 Corticosteroids versus control, Outcome 3 Number of patients improved after
12 weeks excluding those who did not complete the study.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 1 Corticosteroids versus control
Outcome: 3 Number of patients improved after 12 weeks excluding those who did not complete the study
Study or subgroup Prednisone No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dyck 1982 12/14 5/14 100.0 % 2.40 [ 1.15, 5.00 ]
Total (95% CI) 14 14 100.0 % 2.40 [ 1.15, 5.00 ]
Total events: 12 (Prednisone), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.020)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours no treatment Favours prednisone
Analysis 1.4. Comparison 1 Corticosteroids versus control, Outcome 4 Number of patients who showed
improvement after 12 weeks including those who did not complete the study.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 1 Corticosteroids versus control
Outcome: 4 Number of patients who showed improvement after 12 weeks including those who did not complete the study
Study or subgroup Prednisone No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dyck 1982 12/19 5/16 100.0 % 2.02 [ 0.90, 4.52 ]
Total (95% CI) 19 16 100.0 % 2.02 [ 0.90, 4.52 ]
Total events: 12 (Prednisone), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours no treatment Favours prednisone
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Analysis 2.1. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 1 Remission at 12 months.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 1 Remission at 12 months
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 10/24 6/16 100.0 % 1.11 [ 0.50, 2.45 ]
Total (95% CI) 24 16 100.0 % 1.11 [ 0.50, 2.45 ]
Total events: 10 (Monthly dexamethasone), 6 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours daily pred Favours monthly dex
Analysis 2.2. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 2 ≥ 1 point improvement on INCAT disability score at 12 months.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 2≥ 1 point improvement on INCAT disability score at 12 months
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 13/24 7/16 100.0 % 1.24 [ 0.64, 2.41 ]
Total (95% CI) 24 16 100.0 % 1.24 [ 0.64, 2.41 ]
Total events: 13 (Monthly dexamethasone), 7 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours daily pred Favours monthly dex
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Analysis 2.3. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 3 Change in MRC sum score at endpoint.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 3 Change in MRC sum score at endpoint
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2010 23 4 (6.61) 16 1.6 (6.84) 100.0 % 2.40 [ -1.90, 6.70 ]
Total (95% CI) 23 16 100.0 % 2.40 [ -1.90, 6.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours daily pred Favours monthly dex
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Analysis 2.4. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 4 Change in grip strength at endpoint.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 4 Change in grip strength at endpoint
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kPa] N Mean(SD)[kPa] IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2010 23 8.1 (30.46) 15 13.4 (38.53) 100.0 % -5.30 [ -28.43, 17.83 ]
Total (95% CI) 23 15 100.0 % -5.30 [ -28.43, 17.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours daily pred Favours monthly dex
Analysis 2.5. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 5 Sleeplessness.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 5 Sleeplessness
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 8/24 12/16 100.0 % 0.44 [ 0.24, 0.84 ]
Total (95% CI) 24 16 100.0 % 0.44 [ 0.24, 0.84 ]
Total events: 8 (Monthly dexamethasone), 12 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours monthly dex Favours daily pred
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Analysis 2.6. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 6 Cushingoid facies.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 6 Cushingoid facies
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 6/24 8/16 100.0 % 0.50 [ 0.21, 1.17 ]
Total (95% CI) 24 16 100.0 % 0.50 [ 0.21, 1.17 ]
Total events: 6 (Monthly dexamethasone), 8 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours monthly dex Favours daily pred
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Analysis 2.7. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 7 Weight gain 1 - 3 kg.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 7 Weight gain 1 - 3 kg
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 13/24 9/16 100.0 % 0.96 [ 0.55, 1.70 ]
Total (95% CI) 24 16 100.0 % 0.96 [ 0.55, 1.70 ]
Total events: 13 (Monthly dexamethasone), 9 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours monthly dex Favours daily pred
Analysis 2.8. Comparison 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose
dexamethasone, Outcome 8 Weight gain > 3 kg.
Review: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
Comparison: 2 Standard-dose daily oral prednisolone versus monthly pulsed high-dose dexamethasone
Outcome: 8 Weight gain > 3 kg
Study or subgroup
Monthly
dexametha-
sone Daily prednisolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREDICT 2010 1/24 6/16 100.0 % 0.11 [ 0.01, 0.84 ]
Total (95% CI) 24 16 100.0 % 0.11 [ 0.01, 0.84 ]
Total events: 1 (Monthly dexamethasone), 6 (Daily prednisolone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours monthly dex Favours daily pred
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A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 MeSH DESCRIPTOR Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [REFERENCE] [STANDARD]
#2 (chronicNEAR3 inflammatoryNEAR3demyelinatingNEAR3polyradiculoneuropathy) or (chronicNEAR3 inflammatoryNEAR3
demyelinating NEAR3 polyneuropathy) or cidp [REFERENCE] [STANDARD]
#3 “inflammatory demyelinating” [REFERENCE] [STANDARD]
#4 polyradiculoneuropathy or polyneuropathy or polyradiculoneuropathies or polyneuropathies [REFERENCE] [STANDARD]
#5 polyneuritis or polyradiculoneuritis [REFERENCE] [STANDARD]
#6 MeSH DESCRIPTOR Polyneuropathies [REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR Polyradiculoneuropathy [REFERENCE] [STANDARD]
#8 #4 or #5 or #6 or #7 [REFERENCE] [STANDARD]
#9 “chronic disease” [REFERENCE] [STANDARD]
#10 #3 and #8 and #9 [REFERENCE] [STANDARD]
#11 #1 or #2 or #10 [REFERENCE] [STANDARD]
#12 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All [REFERENCE] [STANDARD]
#13 MeSH DESCRIPTOR Steroids Explode All [REFERENCE] [STANDARD]
#14 “adrenocorticotropic hormone*” [REFERENCE] [STANDARD]
#15 *asone or *olone or *isone or *onide [REFERENCE] [STANDARD]
#16 #12 or #13 or #14 or #15 [REFERENCE] [STANDARD]
#17 #11 and #16 [REFERENCE] [STANDARD]
#18 (#11 and #16) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL)
#1 inflammatory demyelinating
#2 (polyradiculoneuropath* or polyneuropath*)
#3 MeSH descriptor: [Polyneuropathies] explode all trees
#4 MeSH descriptor: [Polyradiculoneuropathy] explode all trees
#5 (polyneuritis or polyradiculoneuritis)
#6 #2 or #3 or #4 or #5
#7 MeSH descriptor: [Chronic Disease] explode all trees
#8 “chronic disease”
#9 #1 and #6 and (#7 or #8)
#10 chronic inflammatory demyelinating polyradiculoneuropathy
#11 MeSH descriptor: [Polyradiculoneuropathy, Chronic Inflammatory Demyelinating] explode all trees
#12 cidp
#13 #9 or #10 or #11 or #12
#14 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#15 “adrenocorticotropic hormone*”
#16 MeSH descriptor: [Steroids] explode all trees
#17 (prednisone* or prednisolone* or dexamethasone* or corticosteroid*)
#18 #14 or #15 or #16 or #17
#19 #13 and #18
37Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to October Week 3 2014>
Search Strategy:
--------------------------------------------------------------------------------
1 inflammatory demyelinating.tw. (3256)
2 (polyradiculoneuropath$3 or polyneuropath$3).tw. (11425)
3 polyneuropathies/ or Polyradiculoneuropathy/ (7927)
4 (polyneuritis or polyradiculoneuritis).tw. (1715)
5 2 or 3 or 4 (17287)
6 Chronic disease/ or “chronic disease”.mp. (239755)
7 1 and 5 and 6 (322)
8 chronic inflammatory demyelinating polyradiculoneuropathy.mp. or Polyradiculoneuropathy, Chronic InflammatoryDemyelinating/
(1215)
9 cidp.tw. (1080)
10 7 or 8 or 9 (1655)
11 randomized controlled trial.pt. (397325)
12 controlled clinical trial.pt. (90482)
13 randomized.ab. (292700)
14 placebo.ab. (154093)
15 drug therapy.fs. (1776484)
16 randomly.ab. (205493)
17 trial.ab. (304804)
18 groups.ab. (1306164)
19 or/11-18 (3347080)
20 exp animals/ not humans.sh. (4079851)
21 19 not 20 (2851539)
22 10 and 21 (508)
23 Adrenocorticotropic Hormone/ (44964)
24 exp Adrenal Cortex Hormones/ (345255)
25 exp Steroids/ (722046)
26 (prednisone$ or prednisolone$ or dexamethasone$ or corticosteroid$).mp. (195435)
27 or/23-26 (854879)
28 22 and 27 (221)
29 remove duplicates from 28 (203)
Appendix 4. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2014 Week 43>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (40422)
2 double-blind procedure.sh. (115822)
3 single-blind procedure.sh. (18928)
4 randomized controlled trial.sh. (351750)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1068811)
6 trial.ti. (163787)
7 controlled clinical trial/ (387873)
8 or/1-7 (1304767)
9 exp animal/ or exp invertebrate/ or animal.hw. or non human/ or nonhuman/ (20277690)
10 human/ or human cell/ or human tissue/ or normal human/ (15125106)
11 9 not 10 (5185248)
12 8 not 11 (1155248)
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13 limit 12 to embase (957660)
14 inflammatory demyelinating.tw. (4862)
15 (polyradiculoneuropath$3 or polyneuropath$3).tw. (15663)
16 polyneuropathies/ or Polyradiculoneuropathy/ (13870)
17 (polyneuritis or polyradiculoneuritis).tw. (1614)
18 15 or 16 or 17 (22524)
19 chronic disease.mp. or exp Chronic Disease/ (165710)
20 14 and 18 and 19 (121)
21 chronic inflammatory demyelinating polyneuropathy/ or chronic inflammatory demyelinating polyradiculoneuropathy.mp. (2440)
22 cidp.mp. (1978)
23 21 or 22 (3116)
24 20 or 23 (3155)
25 13 and 24 (234)
26 exp corticosteroid/ (693539)
27 corticotropin/ (53256)
28 exp steroid/ (1114663)
29 (prednisone$ or prednisolone$ or dexamethasone$ or corticosteroid$).mp. (494960)
30 or/26-29 (1159921)
31 25 and 30 (131)
32 remove duplicates from 31 (131)
Appendix 5. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov and World
Health Organization International Clinical Trials Registry Platform search strategy
Searched 28 November 2016
Search strategy:
Chronic inflammatory demyelinating polyradiculoneuropathy
WH A T ’ S N E W
Last assessed as up-to-date: 8 November 2016.
Date Event Description
2 November 2017 New citation required but conclusions have not
changed
No new trials. Discussion revised. GRADE assess-
ments and reporting of results revised based on current
Cochrane guidance. Yusuf A Rajabally joined the re-
view at this update
8 November 2016 New search has been performed Search updated.
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H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 3, 2001
Date Event Description
24 November 2014 New citation required but conclusions have not
changed
Search updated
27 October 2014 New search has been performed Plain language summary rewritten. Methods revised
to incorporate new outcome measures and diagnostic
criteria as stipulated in the 27 April 2012 update. No
new studies. Background and discussion revised to in-
corporate up-to-date references. Results edited to fit
latest house style. The search strategies were updated
for the October 2014 update to make themmore spe-
cific. Background and discussion sections revised. No
new trials
27 April 2012 New citation required and conclusions have changed Newly included trial has changed conclusions. Up-
dated searches fully reviewed and incorporated
5 March 2012 New search has been performed Searches updated to February 2012. One new
trial comparing two different corticosteroid regimens
added. Methods updated to include ’Risk of bias’ and
’Summary of findings’ tables. New references to non-
randomised studies added. Text rewritten throughout
26 March 2008 New search has been performed Searches were updated in October 2007. No new rel-
evant trials were found
25 March 2008 Amended Converted to new review format.
2 February 2006 New search has been performed The search for randomised trials was repeated on 2nd
February 2006 and none were found
1 January 2004 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Two authors (RACH and MMM) extracted data independently. MMM wrote the first draft of the original review. RACH wrote the
first draft of the review updates and constructed the ’Risk of bias’ and ’Summary of findings’ tables. MMM checked the data entry. All
three authors agreed the final text of this update.
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with Novartis which was conducting a trial investigating the immunosuppressive drug fingolimod as a treatment for CIDP. RACH is
an honorary member of the Board of GBS CIDP Foundation International, and Medical Patron of gain (Guillain-Barré & Associated
Inflammatory Neuropathies), the British charity which supports people with CIDP.
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S O U R C E S O F S U P P O R T
Internal sources
• GB Pant Hospital, New Delhi, India.
• King’s College London School of Medicine, UK.
External sources
• The late Mr Chris and Mrs Mary Lazari, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the original version of this review the primary outcome was change in disability twelve weeks after the start of treatment (Mehndiratta
2001; Mehndiratta 2002), measured by the Modified Rankin Scale (Van Swieten 1988), or a similar disability scale, but the review
authors adopted new scales developed for use in CIDP in this and previous updates (Hughes 2012; Hughes 2015).
We added ’Summary of findings’ tables. The ’Risk of bias’ assessment follows current Cochrane methodology (Higgins 2011). We
included a PRISMA flow chart to illustrate the study selection process.
YAR joined the review authors at this update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents [∗therapeutic use]; Dexamethasone [therapeutic use]; Glucocorticoids [∗therapeutic use]; Polyradiculoneu-
ropathy, Chronic Inflammatory Demyelinating [∗drug therapy]; Prednisolone [therapeutic use]; Prednisone [therapeutic use]; Ran-
domized Controlled Trials as Topic
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